Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAP2K1 | Q02750 | 16/20 | 0.47 |
| ▸ | MAP2K2 | P36507 | 5/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.44 |
| ▸ | ABCB1 | P08183 | 2/20 | 0.43 |
| ▸ | MAP2K5 | Q13163 | 2/20 | 0.42 |
| ▸ | BRAF | P15056 | 1/20 | 0.42 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.42 |
| ▸ | EIF2AK1 | Q9BQI3 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4860576 | 0.94 | MEN1 (0.47) | MAP2K1MAP2K2KMT2AMEN1TDP1 | |
| SCHEMBL7051618 | 0.93 | MAP2K2 (0.44) | MAP2K1MAP2K2KMT2AMEN1TDP1 | |
| SCHEMBL4863043 | 0.93 | MAP2K1 (0.56) | MAP2K1MAP2K2MAP2K5BRAFMAPK1 | |
| SCHEMBL7051395 | 0.91 | MAP2K1 (0.51) | MAP2K1MAP2K2MAP2K5BRAFMAPK1 | |
| SCHEMBL4862073 | 0.91 | MEN1 (0.44) | MAP2K1MAP2K2KMT2AMEN1TDP1 | |
| SCHEMBL4862967 | 0.91 | MAP2K1 (0.47) | MAP2K1MAP2K2KMT2AABCB1MAP2K5 | |
| SCHEMBL4864335 | 0.88 | MAP2K1 (0.61) | MAP2K1MAP2K2KMT2AMEN1TDP1 | |
| SCHEMBL4857657 | 0.88 | MAP2K1 (0.47) | MAP2K1MAP2K2KMT2AMEN1TDP1 | |
| SCHEMBL4859893 | 0.87 | MAP2K1 (0.53) | MAP2K1MAP2K2MAP2K5BRAFMAPK1 | |
| SCHEMBL4857212 | 0.86 | MAP2K1 (0.55) | MAP2K1MAP2K2KMT2AMEN1TDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1301472-B1 | OXYGENATED ESTERS OF 4-IODO PHENYLAMINO BENZHYDROXAMIC ACIDS | WARNER LAMBERT CO (US) | 2014-03-26 | — | — | EP | disclosed |
| US-7411001-B2 | Oxygenated esters of 4-iodo phenylamino benzhydroxamic acids | WARNER-LAMBERT COMPANY (US) | 2008-08-12 | — | — | US | disclosed |
| US-6960614-B2 | Oxygenated esters of 4-lodo phenylamino benzhydroxamic acids | WARNER-LAMBERT COMPANY (US) | 2005-11-01 | — | — | US | disclosed |
| US-20050176820-A1 | Oxygenated esters of 4-iodo phenylamino benzhydroxamic acids | WARNER-LAMBERT COMPANY | 2005-08-11 | — | — | US | disclosed |
| US-20040054172-A1 | Oxygenated esters of 4-lodo phenylamino benzhydroxamic acids | WARNER-LAMBERT COMPANY | 2004-03-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050176820-A1 | Oxygenated esters of 4-iodo phenylamino benzhydroxamic acids | CYP4X1, CYP2A7, CYP4B1 | MAP2K1 4341/4885MAP2K2 4268/4885KMT2A 2093/4885 |
| US-20040054172-A1 | Oxygenated esters of 4-lodo phenylamino benzhydroxamic acids | CYP4X1, ALOX5, HAAO | MAP2K1 4312/4885MAP2K2 4025/4885KMT2A 2409/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.